Response Genetics, which is developing diagnostic tests for assessing the risk of cancer recurrence and prediction of response to chemotherapy, priced its 3 million shares at $7, the low end of its proposed $7 to $8 range, on Tuesday morning. Maxim Group was the lead manager on the deal. The stock is expected to begin trading on Tuesday on the NASDAQ under the ticker "RGDX."
